Paratek rises on positive data for antibiotic for skin infections

Paratek Pharmaceuticals

30/08/2019 14:07

** Drug developer's shares  PRTK.O  rise ~14% to $3.85
    ** Co's treatment Nuzyra for acute bacterial skin and skin
structure infections (ABSSSI) compared to linezolid, an
antibiotic available in the market for the same indication, was
seen to be as effective and safe in a late-stage study
 urn:newsml:reuters.com:*:nGNXbt3YqZ
    ** Says data from the study were published in scientific
journal The Lancet Infectious Diseases    
    ** Says the study evaluated oral, once-daily Nuzyra against
twice-daily, oral linezolid in 735 adults with ABSSSI 
    ** Nuzyra was approved by the FDA last year, for the
treatment of adults with community acquired bacterial pneumonia
and ABSSSI; PRTK awaits Nuzyra's approval in EU
    ** Up to Thursday's close, PRTK fell ~34% YTD

 (Reporting by Manojna Maddipatla in Bengaluru)
 ((manojna.kalyani@thomsonreuters.com; within the U.S. +1 646
223 8780, outside the U.S. +91  80 6749 1692))